Neuland Labs posts record Q4 but flags lumpiness ahead
A stunning quarter, but management warns the 40%+ EBITDA margin is not a new normal; lumpy growth is the reality.
What management said
- Q4 revenue surged 134.9% to ₹788.7 cr, driven by commercial CMS
- EBITDA margin hit 40%+, but CFO says not indicative of future performance
- Full-year revenue grew 37% to ₹2,053 cr, in line with earlier outlook
The brief
Neuland Labs reported a blow-out Q4 with revenue of ₹788.7 crore (up 134.9% YoY) and EBITDA of ₹319.4 crore at a 40%+ margin, driven by commercial CMS products. Full-year revenue hit ₹2,053 crore (+37.3% YoY) with EBITDA margin improving to 29.4% from 22.9%. PAT for the quarter was ₹212.5 crore. Despite the numbers, management cautioned that the Q4 margin is not sustainable due to business lumpiness. The company maintains visible growth over the next 2-3 years from its pipeline and is investing in peptide facilities and R&D. CFO Abhijit Majumdar stated the high margin is not indicative of future performance. The verdict: a record quarter, but the underlying lumpy nature of the business remains—investors should focus on multi-quarter trends.
In their words
“This exceptional operating margin reflects the record high revenue this quarter and is partly because of the uneven nature of our revenue flows and should not be seen as an indicator of our future performance.”— Abhijit Majumdar — CFO
“The lumpiness does not recognize financial year boundaries. It doesn't care about March 31. So even sometimes a full year may not turn out to be exactly as expected.”— Saharsh Davuluri — Vice Chairman & MD
Summarised from the Neuland Laboratories Limited Q4 2026 earnings-call transcript. View transcript.